Research Reveals Exactly How Rogue Immune Cells Cause Multiple Sclerosis
Final thoughts
“Clinicians are also keenly aware that inflammatory events are key factors contributing to early progression in disease, and research has shown us the benefit of early intervention. Despite the fact that therapy is started even after the first attack in someone who might turn out to have MS (i.e., clinically isolated syndrome), we were still unable to prevent a substantial number of patients from progressing. This tells us the need to deal with MS aggressively and early. Perhaps with some of the newly developed molecules or safe combinations of treatments, we will be able to successfully quell the early inflammatory events and avert disease progression,” said Dr. Mark S. Freedman, Professor of Medicine at the University of Ottawa.
References
https://www.eurekalert.org/pub_releases/2017-11/uoia-hri112117.php
